2604.01549 HCC-METASCORE: A Biomarker-Driven Composite Scoring Framework for Systemic Therapy Signal Prioritisation in Hepatocellular Carcinoma with Extrahepatic Metastatic Spread
Hepatocellular carcinoma (HCC) is the most prevalent form of primary liver cancer and a leading cause of cancer-related mortality worldwide. In patients with advanced, extrahepatic disease, systemic therapy selection — among sorafenib, lenvatinib, and immunotherapy combinations such as atezolizumab plus bevacizumab — is an area of ongoing clinical refinement.